NuvoBio’s DarwinSeq platform bypasses the limitations of structural biology by leveraging protein interaction networks to design peptides that bind to targets previously considered ‘undruggable’.
What is the problem?
Computational drug discovery still relies heavily on static protein structures, yet many disease-relevant proteins are dynamic, context-dependent, and lack functionally-relevant conformations. For example, structure-based AI often misses real biological interactions and fails to identify proteome-wide off-target drug targets.
What is their solution?
NuvoBio’s DarwinSeq platform enables informative peptide discovery using sequence and biologically validated interaction data, rather than static protein structures. By focusing on protein function, DarwinSeq learns to evolve highly-specific and potent peptide binders across the proteome, even for protein targets that were previously undruggable due to a lack of structural data or conformational flexibly.
